AbbVie: Growth Is Still A Better Choice

Morsa Images/DigitalVision via Getty ImagesSince my last article was published on April 29, AbbVie's share price (NYSE:ABBV) has risen more than 16%, hitting new multi-year highs. This article will focus not only on the company's Q2 2024 financial results but also on other factors that make me believe it is becoming an increasingly attractive stock among Big Pharma despite the lack of significant progress in developing its oncology franchise. AbbVie's Q2 2024 financial results were beyond praise AbbVie' ...